Interleukin (IL)-5 and eotaxin families regulate the development of eosinophilic inflammation of asthma in a co-operative manner. The exposure to airborne lipopolysaccharide (LPS) induces varying degrees of airflow obstruction and neutrophilic airway inflammation. Production of IL-5 and eotaxin subfamily chemokines was analysed in response to Dermatophagoides pteronyssinus allergen (D.p.) according to the presence of specific IgE to D.p., and investigated the mechanism underlying their LPS-mediated regulation of these cytokines in response to the specific allergen. Peripheral blood cells (PBCs) from asthmatics with (group 1) or without (group 2) specific IgE to D.p. and from non-asthmatics with (group 3) or without (group 4) were stimulated with D.p. or LPS. For LPS-mediated inhibition of IL-5 and eotaxin-2 production, LPS-induced cytokines were added to the D.p.-stimulated PBCs. IL-5 and eotaxin-2, but not eotaxin-1 and 3, were significantly increased by D.p.-stimulated-PBCs from group 1, while only eotaxin-2 was elevated in group 3. Eotaxin-2 production was found in monocytes and correlated with the level of specific IgE to D.p. LPS treatment resulted in the decrease in eotaxin-2 and IL-5 production by the D.p.-stimulated PBCs. LPS-induced IL-10 completely inhibited D.p.-stimulated production of eotaxin-2 and IL-5. The differential responses of the eotaxin family to specific antigens suggest that the predominant role of eotaxin-2 and LPS may attenuate eosinophilic inflammation by inhibiting IL-5 and eotaxin-2 synthesis through IL-10 production.
Interleukin (IL)-5 and eotaxin families regulate the development of eosinophilic inflammation of asthma in a co-operative manner. The exposure to airborne lipopolysaccharide (LPS) induces varying degrees of airflow obstruction and neutrophilic airway inflammation. Production of IL-5 and eotaxin subfamily chemokines was analysed in response to Dermatophagoides pteronyssinus allergen (D.p.) according to the presence of specific IgE to D.p., and investigated the mechanism underlying their LPS-mediated regulation of these cytokines in response to the specific allergen. Peripheral blood cells (PBCs) from asthmatics with (group 1) or without (group 2) specific IgE to D.p. and from non-asthmatics with (group 3) or without (group 4) were stimulated with D.p. or LPS. For LPS-mediated inhibition of IL-5 and eotaxin-2 production, LPS-induced cytokines were added to the D.p.-stimulated PBCs. IL-5 and eotaxin-2, but not eotaxin-1 and 3, were significantly increased by D.p.-stimulated-PBCs from group 1, while only eotaxin-2 was elevated in group 3. Eotaxin-2 production was found in monocytes and correlated with the level of specific IgE to D.p. LPS treatment resulted in the decrease in eotaxin-2 and IL-5 production by the D.p.-stimulated PBCs. LPS-induced IL-10 completely inhibited D.p.-stimulated production of eotaxin-2 and IL-5. The differential responses of the eotaxin family to specific antigens suggest that the predominant role of eotaxin-2 and LPS may attenuate eosinophilic inflammation by inhibiting IL-5 and eotaxin-2 synthesis through IL-10 production.
Allergic asthma has been regarded as an atopic disease involving allergen exposure,
allergic (IgE-mediated) sensitization with a Th2 CD4+ lymphocyte
response and subsequent interleukin (IL)-5-mediated eosinophilic airways
inflammation, resulting in enhanced bronchial reactivity and reversible airflow
obstruction [1]. In this
process, antigen-sensitized T helper 2 (Th2) cells play a key role in development of
the manifestations through their production and release of specific cytokines, such
as IL-4, IL-5 and IL-13 [2]. The
eotaxin subfamily, a member of CC chemokines, also participates in the development
of asthma and other allergic disorders through the mobilization of inflammatory
cells bearing CCR3, especially eosinophils. The potent effects of eotaxins on
eosinophils in concert with IL-5 are explained largely by their ability to signal
through the CCR3 [3]. Three
members of this family have been identified: eotaxin-1 [4], eotaxin-2 [5] and eotaxin-3 [6], and the three eotaxins share the same CCR3 [7,8]. While limited studies have demonstrated their differential
expression and their roles in regulating the kinetics of eosinophil recruitment
during allergic inflammation [9-12], the
eotaxins/CCR3 pathway evidently plays a fundamental role in eosinophil
recruitment in experimental allergic asthma [10,13]. In
allergen-sensitized atopic asthmatic subjects, in vitro allergen
stimulation induces IL-5 production by peripheral blood mononuclear cells (PBMC)
[14]; however, it has not
been evaluated whether the synthesis of eotaxins depends on antigen
sensitization.The exposure to airborne lipopolysaccharide (LPS) induces varying degrees of airflow
obstruction and neutrophil inflammation and is often associated with an exacerbation
of established asthma in children and adults [15,16]. However, emerging
evidence suggests that exposure to endotoxin in early life prevents the development
of atopy and, potentially, allergic asthma [17-19]. The
inhibitory effect of LPS is mediated presumably by the induction of Th1 cytokines
such as interferon (IFN)-ã and IL-12 secretion [18,20,21] or regulatory cytokines such as
IL-10 [22]. However, the effect
and mechanisms of LPS on antigen-sensitized IL-5 and eotaxins production has not yet
been evaluated. In this study, we employed an ex vivo stimulation
of peripheral whole blood cells (PBCs) that were obtained from four groups of
asthmatics and non-asthmatics with or without specific IgE to mite
Dermatophagoides pteronyssinus (D.p.). The production of
cytokines and eotaxin subfamily chemokines in response to the mite antigen and the
mechanism(s) underlying their LPS-mediated regulation were analysed.
Methods
Subjects
The study subjects comprised four groups: asthmatics with (group 1) or without
(group 2) D.p.-specific IgE, normal controls with (group 3) or without (group
4). The asthmatics had clinical symptoms and physical characteristics compatible
with the Global Initiative for Asthma (GINA) guidelines [23]. Asthmatics showed airway
reversibility, as documented by an inhalant bronchodilator-induced improvement
of more than 15% of forced expiratory volume in 1 second
(FEV1) and/or an airway hyper-responsiveness (AHR) to <
10 mg methacholine/ml [24]. Allergy skin prick tests were performed using 24 commercial
inhalant allergens, which included dust mites (Dermatophagoides
farinae and D. pteronyssinus, Bencard, West
Sussex, UK) and histamine (1 mg/ml). IgE specific to D.p. was measured
using the CAP system (Pharmacia Diagnostics, Uppsala, Sweden) and was presented
as specific IgE class (1–6) according to UniCap-specific IgE Unites
(kUA/l). All subjects gave informed consent to participate
in the study, and the protocols were approved by the local ethics committee of
Soonchunhyang University Hospital.
Cell culture and cytokine/chemokine production
Peripheral blood was diluted at a 1 : 1 ratio with tissue culture medium
containing RPMI-1640, 2 mm l-glutamine, 25 mM HEPES, 100 U
penicillin/ml and 100 µg streptomycin/ml (JBI, Daegu,
Korea). PBCs were stimulated with various concentrations of D.p., which was
generously gifted by Professor Hong [25], and LPS (Escherichia coli 0111:B4,
L-2630) (Sigma, St. Louis, MO, USA) for different lengths of time. The culture
supernatants were harvested by centrifugation and were stored at
−20°C until assayed. The potency of the D.p. was measured by
specific IgE inhibition test with the pooled sera of 10 asthmatics having
specific IgE (score > 4), as described previously [26]. Fifty per cent inhibition was
obtained by preincubation of the pooled serum with 10 µg D.p.
extract/ml. The endotoxin concentration of the mixture containing 10
µg D.p./ml was < 0·283 EU/ml (equivalent to
28·3 pg/ml), as determined by a limulus amoebocyte lysate kit
(Bio-Whittaker, Walkersville, MD, USA).
Measurement of cytokine and chemokine concentrations
Cytokine and eotaxin concentrations were determined by enzyme-linked
immunosorbent assay (ELISA), using kits from R&D Systems (Minneapolis,
MN, USA) for eotaxin-2, and eotaxin-3 and kits from BD Biosciences (San Diego,
CA, USA) for eotaxin-1, IL-5, IFN-γ, IL-12 and IL-10. The detection
limits for eotaxin-1, eotaxin-2, eotaxin-3, IL-5, IFN-γ, IL-12 and IL-10
were 6·3, 15·6, 62·5, 3·9, 18·7, 31·3
and 15·6 pg/ml, respectively. All concentrations below these
limits were considered as the detection limit values above for the statistical
analysis. The inter- and intra-assay coefficients of variance were below
10%.
Immunocytochemical detection of intracellular eotaxin-2
Peripheral blood leucocytes were isolated from the venous blood of D.p.-specific
IgE-positive asthmatics using a Percoll gradient solution. A total of 1 ×
107 cells were cultured for 72 h in the presence of autologous
serum (10% v/v) and 10 µg D.p./ml, with 3 µM
monensin (Sigma, M5273) added 6 h before the termination of culture. The
cultured cells were cytocentrifuged and fixed with 1% paraformaldehyde
and 0·1% saponin. Eotaxin-2-positive cells were identified by
immunostaining with anti-humaneotaxin-2 (R&D Systems) and biotinylated
goat-anti-mouse IgG (Vector Laboratories, Burlingame, CA, USA). The negative
control was incubated with isotype-matched antibody. The cells were then
counterstained with Wright–Giemsa.
Inhibition and blocking of cytokine production in PBCs stimulated with
D.p.
For inhibition studies, various concentrations of IL-10, IL-12 (R&D
Systems) and IFN-γ (BD Bioscience) were added to PBCs in the presence of
D.p. (10 µg/ml). For blocking, PBCs were pretreated for 30 min
with various concentrations of mouse anti-human IL-10Rα antibody
(R&D Systems) or mouse anti-human TLR4 antibody (BD Bioscience) and then
for 72 h with D.p. (10 µg/ml) or LPS (10 ng/ml).
PBCs from group 1 were stimulated for 72 h with D.p. in the presence or absence
of LPS and/or various concentrations of anti-IL-10Rα. PBMCs were
then isolated from the cultured PBCs. Total RNA was extracted and
reverse-transcribed by incubation with 200 U SuperScript RT (Invitrogen Life
Technologies, Grand Island, NY, USA) at 42°C for 50 min. The resulting
cDNA were placed into tubes containing specific primer pairs for humaneotaxin-2, IL-5 or glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) gene, and
were amplified for 30 cycles (one cycle: 1 min at 95°C, 1 min at
55°C and 1 min at 72°C). The PCR products were resolved by agarose
(1%) gel electrophoresis. The primers used were follows; eotaxin-2
forward primer 5′-GCTCTGTGGTCATCCCCTCTCCCTG-3′, reverse primer
5′-GCAGGTGGTTT GGTTCCAGGATAT-3′; IL-5 forward primer 5′-GAG
GATGCTTCTGCATTTGAGTTTG-3′, reverse primer
5′-GTCAATGTATTTCTTTATTAAGGACAAG-3′; GAPDH forward primer
5′-GGCATTGCTCTC AATGACAA-3′, reverse primer 5′-AGGGCCTC TCT
CTTGCTCTC-3′.
Statistical analysis
Data were expressed as mean ± s.e.m. Statistical analysis was carried out
using the spss program (version 11·0; SPSS Inc., Chicago, IL,
USA). Differences between independent groups or samples were compared using the
non-parametric Kruskal–Wallis H-test for continuous
data. If differences were found to be significant, the Mann–Whitney
U-test was applied to compare differences between two
samples. The Wilcoxon signed rank test was applied for time-dependent changes in
the parameters. Spearman's rank correlation was calculated to assess
correlations between data.
Results
Subject details
Asthmatics (groups 1 and 2) had significantly lower FEV1 and
methacholinePC20 values than did non-asthmatics (groups 3 and 4),
while the former exhibited higher blood eosinophil levels than the latter.
Specific and total IgE were significantly higher in the subjects allergic to
D.p. (groups 1 and 3) than in the non-allergic groups (groups 2 and 4) (Table 1). These findings are consistent
with previously described criteria [27].
Table 1
Clinical profiles of the study subjects.
Asthma
Normal control
Group 1
Group 2
Group 3
Group 4
Subject (M/F)
20 (10/10)
12 (7/5)
7 (5/2)
10 (4/6)
Age (years)
30·9 ±
2·6
33·83 ±
1·2
29·71 ±
2·4
32·0 ±
3·6
Current smoker (%)
38
33·3
32·5
30
FEV1%, predicted
81·1 ±
2·2†‡
97·2 ±
4·8
101·7 ±
4·2
107·8 ±
6·3
Methacholine PC20 (mg/ml)
2·1 ± 1·4†‡
2·7 ± 1·1§¶
25
25
Blood eosinophil (%)
5·1 ± 0·7†‡
6·2 ± 1·5¶
2·1 ± 0·2
1·7 ± 0·4
Skin test to D.p. (%)
100*‡
0 ££
100**
0
Total IgE (U/ml)
571·5 ±
127·6*‡¶
203·9 ±
76·4¶
185·1 ±
37·6**
22·8 ±
6·2
Specific IgE, to D.p. antigen
3·7 ± 0·2*†‡
0 ± 0§
2·7 ± 0·3**
0 ± 0
Specific IgE is presented as specific IgE class (grades 1–6)
according to Unicap-specific IgE Unites (kUA/l).
Values are the means ± s.e.m. P-values were
obtained using the Mann–Whitney U-test or
the χ2 test. The following symbols represent
significant differences (P < 0·05)
between two groups:
between groups 1 and 2,
between groups 1 and 3,
between groups 1 and 4,
between groups 2 and 3,
between groups 2 and 4 and
between groups 3 and 4.
Clinical profiles of the study subjects.Specific IgE is presented as specific IgE class (grades 1–6)
according to Unicap-specific IgE Unites (kUA/l).
Values are the means ± s.e.m. P-values were
obtained using the Mann–Whitney U-test or
the χ2 test. The following symbols represent
significant differences (P < 0·05)
between two groups:between groups 1 and 2,between groups 1 and 3,between groups 1 and 4,between groups 2 and 3,between groups 2 and 4 andbetween groups 3 and 4.
Production of cytokines and chemokines by PBCs in response to D.p.
Throughout this study, a bulk whole blood culture system was employed in which
peripheral blood was diluted at a 1 : 1 ratio with culture medium and used
without fractionation. To optimize IL-5 and eotaxin subfamilies production, PBCs
from group 1 (n = 7) were stimulated with various doses
of D.p. for different periods of time. Eotaxin-2 and IL-5 increased continuously
until 120 h after stimulation with a dose of 10 µg/ml D.p. and was
elevated significantly compared with those of unstimulated PBC, whereas
eotaxin-1 was decreased. No significant differences were found in eotaxin-3
production. Increased IL-5 and eotaxin-2 production by PBCs for 72-h stimulation
with D.p. antigen reached a plateau at a dose of 10 µg/ml D.p and
eotaxin-1 was significantly down-regulated upon exposure of PBCs in a
dose-dependent manner to D.p. antigen (Fig.
1a).
Fig. 1
(a) Time kinetics and dose–responses of IL-5 and eotaxin family
chemokine production by D.p.-stimulated PBCs. PBCs were prepared from
group 1 (n = 7) and were stimulated with various
concentrations of D.p. for different lengths of time. Data are expressed
as the means ± SEM. The statistical analysis was carried out
using the Wilcoxon signed rank test. *P <
0.05, **P < 0.01. (b) Production
of IL-5 and eotaxin subfamilies by D.p.-stimulated PBCs. PBCs were
stimulated with either medium or 10 µg D.p./ml for 72 h.
Groups 1, 2, 3, and 4 included 20, 12, 7, and 10 individual samples,
respectively. The amounts of cytokines were expressed as a fold increase
in which cytokine levels in the presence of D.p. were divided by those
in its absence. *P < 0.05,
**P < 0.01 vs. cytokine levels
in the absence of D.p. (c) Inhibition of D.p.-induced production of
eotaxin-2 and IL-5 by LPS. PBCs from group 1 (n
= 7) were treated with increasing concentrations of LPS in the
presence of D.p. (10 µg/ml) for 72 h, and the eotaxin-2
and IL-5 levels in the culture supernatants were determined.
*P < 0.05,
**P < 0.01 vs. D.p.-induced
production of eotaxin-2 and IL-5. Cytokine production was determined by
ELISA. (d) Percoll gradient-isolated leukocytes from group 1 were
stimulated with medium (panels 1, 2) or D.p. antigen (panels 3, 4),
cytospin, and either incubated with anti-human eotaxin-2 antibody
(panels 1, 3) or stained with Wright-Giemsa solution (panels 2, 4). Bar
=10 µm.
(a) Time kinetics and dose–responses of IL-5 and eotaxin family
chemokine production by D.p.-stimulated PBCs. PBCs were prepared from
group 1 (n = 7) and were stimulated with various
concentrations of D.p. for different lengths of time. Data are expressed
as the means ± SEM. The statistical analysis was carried out
using the Wilcoxon signed rank test. *P <
0.05, **P < 0.01. (b) Production
of IL-5 and eotaxin subfamilies by D.p.-stimulated PBCs. PBCs were
stimulated with either medium or 10 µg D.p./ml for 72 h.
Groups 1, 2, 3, and 4 included 20, 12, 7, and 10 individual samples,
respectively. The amounts of cytokines were expressed as a fold increase
in which cytokine levels in the presence of D.p. were divided by those
in its absence. *P < 0.05,
**P < 0.01 vs. cytokine levels
in the absence of D.p. (c) Inhibition of D.p.-induced production of
eotaxin-2 and IL-5 by LPS. PBCs from group 1 (n
= 7) were treated with increasing concentrations of LPS in the
presence of D.p. (10 µg/ml) for 72 h, and the eotaxin-2
and IL-5 levels in the culture supernatants were determined.
*P < 0.05,
**P < 0.01 vs. D.p.-induced
production of eotaxin-2 and IL-5. Cytokine production was determined by
ELISA. (d) Percoll gradient-isolated leukocytes from group 1 were
stimulated with medium (panels 1, 2) or D.p. antigen (panels 3, 4),
cytospin, and either incubated with anti-humaneotaxin-2 antibody
(panels 1, 3) or stained with Wright-Giemsa solution (panels 2, 4). Bar
=10 µm.Next, we stimulated PBCs from subjects of four groups. To minimize the effect
derived from both different absolute and relative numbers of leucocytes in each
group and in each individual within the group, the results were expressed as a
fold increase of D.p. stimulation versus D.p. non-stimulation.
PBCs were obtained from four groups (group 1, n = 20;
group 2, n = 12; group 3, n = 7;
and group 4, n = 10) and were stimulated with D.p. (10
µg/ml) for 72 h. The significantly increased production of IL-5
was observed only in group 1, while eotaxin-2 was elevated in groups 1 and 3
(Fig. 1b). In contrast, eotaxin-1
production decreased significantly in groups 1 and 3. Eotaxin-3 was not changed
in the four groups (Fig. 1b). Eotaxin-2
production in groups 1 and 3 correlated strongly with the respective levels of
specific serum IgE to D.p. (r = 0·528,
P = 0·017 for group 1 and r
= 0·810, P = 0·027 for group 3)
(Fig. 2). Immunocytochemical and
Wright–Giemsa staining of PBCs from group 1 showed that monocytes were
the eotaxin-2-producing cells (Fig.
1d).
Fig. 2
Correlation of eotaxin-2 production with plasma IgE specific to D.p. and
with production of eotaxin-2. Eotaxin-2 production in D.p.-stimulated
PBCs from asthmatics positive to D.p. (group 1, n
= 20; group 3, n = 7) was plotted against
the level of plasma IgE specific to it. The statistical analysis was
carried out using Spearman's rank test.
Correlation of eotaxin-2 production with plasma IgE specific to D.p. and
with production of eotaxin-2. Eotaxin-2 production in D.p.-stimulated
PBCs from asthmatics positive to D.p. (group 1, n
= 20; group 3, n = 7) was plotted against
the level of plasma IgE specific to it. The statistical analysis was
carried out using Spearman's rank test.
Inhibitory effect of LPS on D.p.-induced eotaxin-2 and IL-5
production
As eotaxin-2 and IL-5 levels increased following stimulation with D.p., the
production of these two cytokines in response to LPS was examined. PBCs from
group 1 (n = 7) were stimulated with increasing
concentrations of LPS in the presence of D.p. (10 µg/ml). The
results showed that eotaxin-2 and IL-5 production declined in a dose-dependent
fashion. Eotaxin-2 was inhibited completely (P =
0·01) and IL-5 was inhibited by 80% (P =
0·01) at 10 ng/ml LPS (Fig.
1c). To examine whether the inhibitory effect of LPS was mediated
through Toll-like receptor 4 (TLR4), a neutralization antibody to TLR4 was added
to PBC cultures from group 1 (n = 6) in the presence of
D.p. (10 µg/ml) and LPS (10 ng/ml). Eotaxin-2 and IL-5
production were partly restored by neutralization with anti-TLR4 in a
dose-dependent manner (Fig. 3a),
suggesting an inhibitory mechanism via TLR4. To identify which factor(s) mediate
the inhibitory effect of LPS on the D.p.-induced production of eotaxin-2 and
IL-5, production of cytokines (IL-5, IFN-γ, IL-12 and IL-10) and eotaxins
was analysed in group 1 PBCs (n = 7) stimulated with LPS
alone. Among these, IFN-γ, IL-12 and IL-10 were significantly
up-regulated upon the exposure of PBCs in a dose-dependent manner of LPS (Fig. 3b).
Fig. 3
(a) The effect of anti-TLR4 on LPS-induced inhibition of eotaxin-2 and
IL-5 production. PBCs were prepared from group 1 (n
= 6) and were incubated with different concentrations of
anti-TLR4 in the presence of LPS (10 ng/ml) and D.p. antigen (10
µg/ml) for 72 h. (b) IFN-γ, IL-12, and IL-10
production by PBCs stimulated with LPS. Group 1 PBCs (n
= 7) were stimulated with LPS (0.1–100 ng/ml) for
72 h. The amounts of cytokine were measured by ELISA. Data are expressed
as the means ± SEM. The statistical analysis was carried out
using the Wilcoxon signed rank test. *P <
0.05, **P < 0.01.
(a) The effect of anti-TLR4 on LPS-induced inhibition of eotaxin-2 and
IL-5 production. PBCs were prepared from group 1 (n
= 6) and were incubated with different concentrations of
anti-TLR4 in the presence of LPS (10 ng/ml) and D.p. antigen (10
µg/ml) for 72 h. (b) IFN-γ, IL-12, and IL-10
production by PBCs stimulated with LPS. Group 1 PBCs (n
= 7) were stimulated with LPS (0.1–100 ng/ml) for
72 h. The amounts of cytokine were measured by ELISA. Data are expressed
as the means ± SEM. The statistical analysis was carried out
using the Wilcoxon signed rank test. *P <
0.05, **P < 0.01.
LPS inhibits D.p.-induced production of IL-5 and eotaxin-2 via IL-10
production
The three cytokines induced by LPS were examined individually for their
inhibitory effect on the production of eotaxin-2 and IL-5 by D.p.-stimulated
PBCs from group 1 (n = 8). IL-10 inhibited eotaxin-2 and
IL-5 production almost completely (Fig.
4a). In contrast, IFN-γ significantly augmented the production
of both cytokines, and IL-12 had no effect. Anti-IL-10Rα suppressed
dose-dependently the inhibitory effect of LPS on D.p.-stimulated IL-5 production
but not eotaxin-2 production (Fig. 4b),
suggesting that a signal transmitted through the IL-10R effectively blocks IL-5
production by D.p.-primed Th2 cells, yet is not effective for monocyte eotaxin-2
production. RT–PCR analysis showed that the LPS-mediated inhibition as
well as the restoration of IL-5 mRNA expression by anti-IL-10Rα indeed
occurred at the transcriptional level (Fig.
4c). The neutralization of eotaxin-2 mRNA expression by
anti-IL-10Rα was not observed, indicating that the inhibitory effects of
LPS on D.p.-induced IL-5 and eotaxin-2 production are regulated differently.
Fig. 4
The inhibitory effects of IL-10 on D.p. antigen-stimulated production of
eotaxin-2 and IL-5. PBCs were prepared from group 1 (n
= 8). (a) PBCs were stimulated with D.p. (10 µg/ml)
for 72 h in the absence or presence of recombinant IL-10, IFN-γ,
or IL-12 (each 0.01–1 ng/ml). (b) PBCs were stimulated
with D.p. (10 µg/ml) and LPS (10 ng/ml) in the
presence of increasing concentrations of anti-IL-10Rα
(0.01–1 µg/ml) for 72 h, and eotaxin-2 and IL-5
production was evaluated. The statistical analysis was carried out using
the Wilcoxon signed rank test. *P < 0.05,
**P < 0.01. (c) PBMCs from
group 1 (n = 8) and were stimulated under the
indicated conditions for 72 h.
The inhibitory effects of IL-10 on D.p. antigen-stimulated production of
eotaxin-2 and IL-5. PBCs were prepared from group 1 (n
= 8). (a) PBCs were stimulated with D.p. (10 µg/ml)
for 72 h in the absence or presence of recombinant IL-10, IFN-γ,
or IL-12 (each 0.01–1 ng/ml). (b) PBCs were stimulated
with D.p. (10 µg/ml) and LPS (10 ng/ml) in the
presence of increasing concentrations of anti-IL-10Rα
(0.01–1 µg/ml) for 72 h, and eotaxin-2 and IL-5
production was evaluated. The statistical analysis was carried out using
the Wilcoxon signed rank test. *P < 0.05,
**P < 0.01. (c) PBMCs from
group 1 (n = 8) and were stimulated under the
indicated conditions for 72 h.
Discussion
We employed an ex vivo stimulation of peripheral blood cells (PBCs)
that were obtained from four groups of asthmatics and non-asthmatics with or without
specific IgE to mite D.p. PBC contains lymphocytes, monocytes and other leucocytes.
It also contains an array of protein and non-protein factors that may influence the
availability of the antigen and LPS used. Thus it functionally represents the
in vivo milieu more accurately than do purified peripheral
blood leucocytes or combinations thereof.Stimulation of PBCs with D.p. resulted in characteristic expression patterns of IL-5
and eotaxin subfamily chemokines. We identified increased IL-5 and eotaxin-2
production in D.p.-stimulated PBCs from the specific IgE-positive (group 1) and
monocytes as a major producer of eotaxin-2. This result indicates the strict
dependence of IL-5 and eotaxin-2 production on sensitization with specific antigens.
IL-5 synthesis was observed only in PBCs from group 1. This result is in agreement
with a previous study in which allergen-induced IL-5 production by PBMC from
sensitized atopic subjects with symptoms, but not subjects without symptoms, is
elevated [14].CD23, a low-affinity receptor of IgE (FcåRII), is expressed at a much higher
level in monocytes from allergic asthmatics than in cells from normal individuals
[28]. It is therefore
speculated that D.p. may form a complex with circulating specific IgE to induce
eotaxin-2 production through the engagement of abundant CD23 on monocytes from
allergic subjects. As a result, eotaxin-2 production may be related to the presence
of specific IgE. Our data demonstrate that eotaxin-1 is down-regulated and eotaxin-2
is up-regulated by D.p., while eotaxin-3 remains unchanged. This may be due to
different cell sources of each eotaxin. While monocytes are a major source of
eotaxin-2, eotaxin-1 and 3 are produced mainly by epithelial cells [9]. Limited studies have demonstrated the
differential expression and roles of eotaxin subfamilies in regulating the kinetics
of eosinophil recruitment during allergic inflammation [11,29]. However,
experimental asthma models using eotaxin 1 and/or eotaxin 2 knock-out mice
showed a dominant role of eotaxin-2 in ovalbumin (OVA)-induced airway eosinophilia
[13], in spite of a
co-operative role for eotaxin-1 and eotaxin-2 in recruitment of eosinophils to the
lung tissue. We have shown that polymorphism in the gene encoding eotaxin-2, but not
eotaxin-1, is associated with a risk of asthma [30] and correlates with plasma eotaxin-2 levels
[31]. These data, including
ours, may suggest a dominant role of eotaxin-2 among the eotaxin subfamily in
peripheral circulation of atopic asthma.The effect of endotoxin exposure in asthma is still controversial. The beneficial
effects of LPS are thought to be mediated by enhanced secretion of IFN-γ and
IL-12 [32,33], whereas LPS affects asthmatics adversely by
enhancing established airway inflammation and airway obstruction [16]. In the present study, we showed
that LPS inhibited dose-dependently the production of IL-5 and eotaxin-2 in response
to specific antigen; thus only IL-10 almost completely inhibited antigen-induced
production of IL-5 and eotaxin-2 (Figs
1–3). The other novel
finding of our study is that blocking the functioning receptor of IL-10
(IL-10Rα) restored the inhibitory effect of LPS only on IL-5 production
(Fig. 4). These data suggest that the
effect of LPS against the manifestation of allergic asthma is achieved by reducing
eosinophilic inflammation through the up-regulation of IL-10 production. In support
of this finding, IL-10 has been shown to exhibit anti-allergic activity in
sensitized mice by preventing IL-5 release and antigen-induced
CD4+ T lymphocyte and eosinophil accumulation [22].Systemic administration of endotoxin to healthy subjects produced a selective
induction of Th1, as confirmed by increased IL-2 production versus
decreased IFN-gamma production and Th2 chemokine ligands such as CCR4 receptor
[34]. These in
vivo data were not in agreement with ours in terms of different
patterns of IFN-gamma production. It would be interesting to evaluate whether IL-10
production is elevated in a human endotoxin model, but this has not yet been
attempted. In contrast to systemic administration, inhalation of endotoxin induced
different patterns of reaction in the airways. Inhalation of endotoxin has been
recognized as an important factor in the aetiology of occupational lung diseases,
including non-allergic asthma [35]. Eosinophilic inflammation is generally considered to be the main
feature of allergic asthmatic airways and is presumed to be crucial in the
pathogenesis of allergic asthma [36]. Endotoxin in house dust is associated with exacerbations of
pre-existing asthma in children and adults [16,37], and induces
neutrophilic airways inflammation via IL-8 secretion [38]. The switching of eosinophilic inflammation into
neutrophilic inflammation in the acute exacerbation of allergic asthma is
contributed mainly by up-regulation of neutrophilic chemokines such as IL-8. In
addition, down-regulation of IL-5 and eotaxin may be one mechanism to reduce the
eosinophilic inflammation in the LPS-induced neutrophilic airway inflammation of
asthmatics, as shown in experimental models [39], although this has not been revealed in the airways of
asthmatics. IL-10 may exert an inhibitory effect on eotaxin-2 production via another
pathway such as IL-10Rβ[40], or an unknown pathway. Intriguingly, IFN-γ treatment
enhanced the production of IL-5 and eotaxin-2 by antigen-stimulated PBCs, while
IL-12 had no effect (Fig. 4a). This
observation is in line with previous findings that the suppression of airway
eosinophilia and AHR by LPS [41] or killed mycobacteria [42] is not attributable to a Th1 shift.In summary, two important conclusions can be drawn from our results: first, specific
antigen-stimulated whole-blood cultures from asthmatics and normal controls with or
without specific IgE to D.p. produce unique patterns of IL-5 and eotaxin-2.
Secondly, LPS inhibits antigen-induced production of IL-5 and eotaxin-2 via IL-10
secretion. The inhibitory effect of endotoxin may be associated with its ability to
attenuate eosinophilic inflammation or eosinophil-mediated immune responses.
Authors: O Michel; J Kips; J Duchateau; F Vertongen; L Robert; H Collet; R Pauwels; R Sergysels Journal: Am J Respir Crit Care Med Date: 1996-12 Impact factor: 21.405
Authors: S Till; R Dickason; D Huston; M Humbert; D Robinson; M Larché; S Durham; A B Kay; C Corrigan Journal: J Allergy Clin Immunol Date: 1997-04 Impact factor: 10.793
Authors: V P Patel; B L Kreider; Y Li; H Li; K Leung; T Salcedo; B Nardelli; V Pippalla; S Gentz; R Thotakura; D Parmelee; R Gentz; G Garotta Journal: J Exp Med Date: 1997-04-07 Impact factor: 14.307
Authors: J R White; C Imburgia; E Dul; E Appelbaum; K O'Donnell; D J O'Shannessy; M Brawner; J Fornwald; J Adamou; N A Elshourbagy; K Kaiser; J J Foley; D B Schmidt; K Johanson; C Macphee; K Moores; D McNulty; G F Scott; R P Schleimer; H M Sarau Journal: J Leukoc Biol Date: 1997-11 Impact factor: 4.962
Authors: J C Kips; G J Brusselle; G F Joos; R A Peleman; J H Tavernier; R R Devos; R A Pauwels Journal: Am J Respir Crit Care Med Date: 1996-02 Impact factor: 21.405
Authors: S C Morris; K B Madden; J J Adamovicz; W C Gause; B R Hubbard; M K Gately; F D Finkelman Journal: J Immunol Date: 1994-02-01 Impact factor: 5.422